Leerink initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $79 price target Janux’s TRACTr platform solves the therapeutic window problem that has historically plagued T-cell engagers in solid tumors, by effectively “masking” their biologic’s activity outside the tumor while enabling activation within the tumor, improving efficacy, the analyst tells investors in a research note. Phase 1 dose-escalation data reported to date, while early, support a best-in-class and competitive cross-class clinical profile, and if further validated, JANX007’s product attributes, including exceptional safety and immune mechanism, would present a welcome addition to the prostate cancer armamentarium and effectively compete with prostate-specific membrane antigen radioligand therapy, including Pluvicto, and antibody-drug conjugate, Leerink says.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JANX:
- Janux Therapeutics’ Q3 Report: Financials and Progress
- Janux Therapeutics price target raised to $82 from $62 at BTIG
- Janux Therapeutics reports Q3 EPS (51c), consensus (33c)
- Janux Therapeutics, Inc. (JANX) Q3 Earnings Cheat Sheet
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
